Who
Philip Astley-Sparke
Director
Company insider
Files Form 4 as: Executive Chairman, Replimune Group; Director, enGene Therapeutics; Director, uniQure.
In numbers
- Trades disclosed
- 73
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $8.5M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 27 Jan 2017
- Last trade
- 20 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 24 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $90K17,657 at $5.08 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $90K17,657 at $5.08 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code G | —25,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code G | —25,000 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $260K32,279 at $8.06 | filing |
| 30 Aug 2024filed 30 Aug 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 16 May 2024filed 20 May 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $245K37,928 at $6.47 | filing |
| 16 May 2023filed 18 May 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $323K17,902 at $18.05 | filing |
| 1 Apr 2023filed 4 Apr 2023 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —213,150 at $0.00 | filing |
| 1 Apr 2023filed 4 Apr 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —142,100 at $0.00 | filing |
| 16 May 2022filed 18 May 2022 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $141K9,632 at $14.59 | filing |
News
Class Action Lawsuit Filed: Replimune Group, Inc. (REPL) - Join by ...REPL · pr-inside.com · 5 Oct 2026
0 headlines in the last 90 days name Philip Astley-Sparke; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.